The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
APPROACH trial: Multimodal approach in patients with mHSPC: A pragmatic, randomized, phase 3 trial of androgen-deprivation therapy (ADT) plus apalutamide (APA) versus ADT plus apalutamide (APA) and local treatment—Meet-URO 29 study.
 
Valentina Guadalupi
No Relationships to Disclose
 
Alessandro Rametta
No Relationships to Disclose
 
Elena Verzoni
Consulting or Advisory Role - Janssen Oncology; MSD/AstraZeneca; Pfizer
Speakers' Bureau - Ipsen; Janssen Oncology; MSD Oncology; Novartis
 
Melanie Claps
No Relationships to Disclose
 
Pierangela Sepe
No Relationships to Disclose
 
Marco Stellato
No Relationships to Disclose
 
Achille Bottiglieri
No Relationships to Disclose
 
Mario Catanzaro
No Relationships to Disclose
 
Barbara Avuzzi
No Relationships to Disclose
 
Maria Chiara Sighinolfi
No Relationships to Disclose
 
Bernardo Rocco
No Relationships to Disclose
 
Barbara Jereczek
No Relationships to Disclose
 
Massimo Di Maio
Honoraria - Bayer; Boehringer Ingelheim; Lilly O.
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Lilly O.
Speakers' Bureau - Boehringer Ingelheim
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme
 
Nicola Nicolai
No Relationships to Disclose
 
Filippo G. De Braud
Honoraria - Amgen Astellas BioPharma; BMS; Incyte; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD SERONO; Incyte; Menarini; Nerviano Medical Sciences; Nerviano Medical Sciences; Novartis Italy; Pierre Fabre; Roche; Sanofi
Research Funding - Basilea Pharmaceutical; Bayer Health; Bristol-Myers Squibb/Medarex; Daiichi Sankyo Europe GmbH; Exelixis; Ignyta; incyte; Janssen Oncology; Kymab (Inst); Loxo (Inst); MedImmune; Merck KGaA; Merck Serono (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)
 
Giuseppe Procopio
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb (BMS); Eisai; Ipsen; Janssen; Merck Sharp & Dohme; MSD Oncology; Novartis; Pfizer
Research Funding - Astellas Pharma; Ipsen; Janssen Oncology